Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm.

Journal: CPT: pharmacometrics & systems pharmacology
PMID:

Abstract

Warfarin remains the most widely prescribed oral anticoagulant in sub-Saharan Africa. However, because of its narrow therapeutic index, dosing can be challenging. We have therefore (a) evaluated and compared the performance of 21 machine-learning techniques in predicting stable warfarin dose in sub-Saharan Black-African patients and (b) externally validated a previously developed Warfarin Anticoagulation in Patients in Sub-Saharan Africa (War-PATH) clinical dose-initiation algorithm. The development cohort included 364 patients recruited from eight outpatient clinics and hospital departments in Uganda and South Africa (June 2018-July 2019). Validation was conducted using an external validation cohort (270 patients recruited from August 2019 to March 2020 in 12 outpatient clinics and hospital departments). Based on the mean absolute error (MAE; mean of absolute differences between the actual and predicted doses), random forest regression (12.07 mg/week; 95% confidence interval [CI], 10.39-13.76) was the best performing machine-learning technique in the external validation cohort, whereas the worst performing technique was model trees (17.59 mg/week; 95% CI, 15.75-19.43). By comparison, the simple, commonly used regression technique (ordinary least squares) performed similarly to more complex supervised machine-learning techniques and achieved an MAE of 13.01 mg/week (95% CI, 11.45-14.58). In summary, we have demonstrated that simpler regression techniques perform similarly to more complex supervised machine-learning techniques. We have also externally validated our previously developed clinical dose-initiation algorithm, which is being prospectively tested for clinical utility.

Authors

  • Innocent G Asiimwe
    Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalized Medicine, Medical Research Council Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Marc Blockman
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Karen Cohen
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Clint Cupido
    Victoria Hospital Internal Medicine Research Initiative, Victoria Hospital Wynberg, Cape Town, South Africa.
  • Claire Hutchinson
    Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalized Medicine, Medical Research Council Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Barry Jacobson
    Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.
  • Mohammed Lamorde
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Jennie Morgan
    Metro District Health Services, Western Cape Department of Health, Cape Town, South Africa.
  • Johannes P Mouton
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Doreen Nakagaayi
    Uganda Heart Institute, Kampala, Uganda.
  • Emmy Okello
    Uganda Heart Institute, Kampala, Uganda.
  • Elise Schapkaitz
    Department of Molecular Medicine and Hematology, Charlotte Maxeke Johannesburg Academic Hospital National Health Laboratory System Complex and University of Witwatersrand, Johannesburg, South Africa.
  • Christine Sekaggya-Wiltshire
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Jerome R Semakula
    Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Catriona Waitt
    Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalized Medicine, Medical Research Council Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Eunice J Zhang
    Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalized Medicine, Medical Research Council Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Andrea L Jorgensen
    Department of Health Data Science, Institute of Population Health Sciences, University of Liverpool, Liverpool, UK.
  • Munir Pirmohamed
    Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalized Medicine, Medical Research Council Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.